News | August 28, 2013

Japanese Market For Peripheral Vascular Devices Will Be Characterized By New Product Launches In Many Segments

Millenium Research Group, Stents (peripheral), Cath Lab,

August 28, 2013 — According to Millennium Research Group (MRG), efforts to streamline the regulatory approval process in Japan have resulted in the recent entry of numerous devices in the Japanese peripheral vascular (PV) device market, and more products, such as drug-coated balloons and infrapopliteal stents, are expected to enter in the next few years.

The femoropopliteal (fem-pop) stent segment in particular has seen significant activity in the past year. Prior to the approval of the first product in March 2012, procedures using fem-pop stents were only performed off-label; since then, three fem-pop stents have received approval. Cook Medical's Zilver PTX stent was the first to enter the market, and this product also represents the first drug-eluting stent (DES) approved for peripheral indications in Japan. Because this product enjoys a first-to-market advantage, many Japanese physicians continue to prefer it to other fem-pop stents that received later approval.

The aortic stent graft market has also seen a number of recent product approvals, and most new products address previous limitations of aortic stent grafts and will allow a greater number of patients to be treated with these minimally invasive devices. For example, Medtronic's Endurant abdominal aortic stent graft is a low-profile device, providing physicians with a better treatment option for patients with difficult anatomies.

"The availability of these novel devices and the entry of new competitors will help raise the profile of aortic stent graft treatment," said MRG Analyst Tonya Martin. "These developments will encourage more physicians to learn the procedures, and this market will begin to see penetration comparable to Europe."

The Japanese PV device market will, however, be limited by the Ministry of Health, Labour and Welfare (MHLW)'s biennial reimbursement cuts, which will place substantial pressure of PV device prices. MHLW cuts will have the most significant impact on the percutaneous transluminal angioplasty (PTA) balloon catheter market, which will ultimately decline as a result.

Millennium Research Group's "Japanese Markets for Peripheral Vascular Devices 2013," report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for PV stents, PTA balloon catheters, chronic total occlusion crossing devices, embolic protection devices, inferior vena cava filters, aortic stent grafts, synthetic surgical grafts and PV accessory devices in Japan.

For more information, visit: www.MRG.net

 


Related Content

News | Peripheral Artery Disease (PAD)

March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug ...

Home March 20, 2024
Home
News | Peripheral Artery Disease (PAD)

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

Home February 12, 2024
Home
News | Peripheral Artery Disease (PAD)

November 10, 2023 —Getinge announced commercial availability of the iCast covered stent system in the United States for ...

Home November 10, 2023
Home
News | Peripheral Artery Disease (PAD)

October 24, 2023 — Four years ago, following a publication based on the limited data available, the U.S. Food and Drug ...

Home October 24, 2023
Home
News | Peripheral Artery Disease (PAD)

September 14, 2023 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of ...

Home September 14, 2023
Home
News | Peripheral Artery Disease (PAD)

July 11, 2023 — The U.S. Food and Drug Administration (FDA) is informing healthcare providers about updated information ...

Home July 11, 2023
Home
News | Peripheral Artery Disease (PAD)

June 21, 2023 — A new science report issued by the American Heart Association (AHA) emphasizes the importance of ...

Home June 21, 2023
Home
News | Peripheral Artery Disease (PAD)

June 16, 2023 — Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive ...

Home June 16, 2023
Home
News | Peripheral Artery Disease (PAD)

June 15, 2023 — Endologix LLC, a privately held, global medical device company dedicated to providing disruptive ...

Home June 15, 2023
Home
News | Peripheral Artery Disease (PAD)

March 8, 2023 — Treatments for peripheral artery disease (PAD) were largely developed in men and are less effective in ...

Home March 08, 2023
Home
Subscribe Now